MCE 的所有產(chǎn)品僅用作科學(xué)研究或藥證申報(bào)，我們不為任何個(gè)人用途提供產(chǎn)品和服務(wù)。

Lucitanib

CAS No. : 1058137-23-7

MCE 國(guó)際站：Lucitanib

產(chǎn)品活性：Lucitanib (E-3810) 是 VEGFR 和 FGFR 的雙重抑制劑，有效和選擇性地抑制VEGFR1，VEGFR2，VEGFR3，FGFR1，FGFR2，IC₅₀分別為7 nM，25 nM，10 nM，17.5 nM，82.5 nM。

研究領(lǐng)域：Protein Tyrosine Kinase/RTK

作用靶點(diǎn)：VEGFR  |  FGFR

In Vitro: Consistent with the inhibitory activity of VEGFR and FGFR auto-phosphorylation, Lucitanib potently inhibits VEGF and bFGF-stimulated HUVEC proliferation with IC₅₀ of 40 and 50 nM, respectively. Besides, Lucitanib (E-3810) also inhibits CSF-1R with IC₅₀ of 5 nM. Lucitanib potently inhibits FGFR2 activity (K_i<0.05 μM), follows by PDGFRα activity (K_i=0.11 μM). The K_i values obtained for DDR2, LYN, CARDIAK, CSBP (2), EPHA2, and YES range between 0.26 and 8 μM.

In Vivo: Lucitanib (E-3810), at oral dosing of 20 mg/kg for 7 consecutive days, completely inhibits (P<0.01) the bFGF induced angiogenic response compare with the response in vehicle-treated mice. Lucitanib (E-3810) shows a broad spectrum of activity, being active in all the xenografts tested (HT29 colon carcinoma, A2780 ovarian carcinoma, A498, SN12K1, and RXF393 renal carcinomas) with dose-dependent inhibition of tumor growth. E-3810 significantly delays growth during treatment, but tumors resume their growth when treatment is suspended; in a few cases, tumor regression is observed. The activity of Lucitanib (E-3810) given at the doses of 15 mg/kg is tested on MDA-MB-231 breast cancer transplanted subcutaneously, at a late stage, when tumor masses reach 350 to 400 mg. This tumor xenograft is very sensitive to Lucitanib (E-3810), with complete tumor stabilization lasting throughout the 30-day treatment. As in other tumor models, tumors re-grow after withdrawal of Lucitanib (E-3810) at a rate similar to control tumors.

相關(guān)產(chǎn)品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Kinase Inhibitor Library  |  Protein Tyrosine Kinase Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Differentiation Inducing Compound Library  |  Reprogramming Compound Library  |  Anti-COVID-19 Compound Library  |  Anti-Breast Cancer Compound Library  |  Anti-Lung Cancer Compound Library  |  Anti-Pancreatic Cancer Compound Library  |  Anti-Blood Cancer Compound Library  |  Angiogenesis-Related Compound Library  |  Anti-Liver Cancer Compound Library   |  Anti-Colorectal Cancer Compound Library   |  Human Metabolite Library  |  Anti-Prostate Cancer Compound Library  |  Anti-Pulmonary Fibrosis Compound Library  |  Heterocyclic Compound Library  |  Membrane Protein-targeted Compound Library  |  Membrane Receptor-targeted Compound Library  |  Highly Selective Inhibitors Library  |  Cytokine Inhibitors Library  |  Sorafenib  |  Lenvatinib  |  Sunitinib  |  Regorafenib  |  Nintedanib  |  Bevacizumab  |  Semaxinib  |  Cabozantinib  |  Ponatinib  |  Erdafitinib  |  Infigratinib  |  Axitinib  |  Midostaurin  |  Pemigatinib  |  Chloramphenicol  |  Pazopanib  |  Futibatinib  |  Fexagratinib  |  PD173074  |  Heparan Sulfate  |  Formononetin  |  5Z-7-Oxozeaenol  |  Linifanib  |  Tanshinone IIA  |  Vandetanib  |  Foretinib  |  SU 5402  |  Fruquintinib

熱門(mén)產(chǎn)品線：重組蛋白  |  化合物庫(kù)  |  天然產(chǎn)物  |  熒光染料  |  PROTAC  |  同位素標(biāo)記物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds